Abstract:Phase II trials of the VEGF-Trap agent aflibercept demonstrate its effectiveness in reducing malignant ascites. One randomized, placebo-controlled phase II study enrolled fifty-five women with advanced ovarian cancer and recurrent malignant ascites, and found women receiving aflibercept averaged thirty-one days, until repeat paracentesis, compared to eight days which in the placebo group. Fatal bowel perforations occurred in three patients receiving aflibercept, and only in one placebo group patient, demonstra… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.